Autolus
Clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Learn more
Launch date
Employees
Market cap
CAD1.5b
Enterprise valuation
CAD586m (Public information from Sep 2024)
Share price
$3.85 AUTL
Company register number 09115837
London England (HQ)
Authorizing premium user...